In a groundbreaking development, scientists have genetically modified a tobacco plant (Nicotiana benthamiana) to simultaneously produce five psychedelic compounds: DMT (originally from plants), psilocin and psilocybin (from mushrooms), and bufotenin and 5-MeO-DMT (from toads). This achievement could revolutionize the production of these substances for research and potential therapeutic applications.
The team, led by Paula Berman and Janka Höfer, identified key genes and biochemical pathways from various organisms known to produce these compounds. They combined these with supporting enzymes from rice and cress, then introduced the genetic toolkit into tobacco plants. The choice of tobacco was strategic due to its rapid growth and ease of manipulation in laboratory settings.
The modified plants successfully produced all five compounds, though some were produced in lower quantities than their natural sources. With further optimization, this system could become a reliable source for researchers studying psychedelics' therapeutic potential in treating conditions like depression, anxiety, and PTSD.
This breakthrough not only addresses supply challenges but also reduces ecological and ethical concerns associated with harvesting natural producers. By engineering plants to produce these compounds, researchers can explore new avenues for drug development and diversify existing compounds for targeted therapies.